1. Koury MJ, Sawyer ST and Brandt SJ (2002). New insights into erythropoiesis. Curr Opin Hematol 9: 93–100
2. Walrafen P, Verdier F, Kadri Z, Chretien S, Lacombe C and Mayeux P (2005). Both proteasomes and lysosomes degrade the activated erythropoietin receptor. Blood 105: 600–608
3. Chapel S, Veng-Pedersen P, Hohl RJ, Schmidt RL, McGuire EM and Widness JA (2001). Changes in erythropoietin pharmacokinetics following busulfan-induced bone marrow ablation in sheep: evidence for bone marrow as a major erythropoietin elimination pathway. J Pharmacol Exp Ther 298: 820–824
4. Kato M, Kamiyama H, Okazaki A, Kumaki K, Kato Y and Sugiyama Y (1997). Mechanism for the nonlinear pharmacokinetics of erythropoietin in rats. J Pharmacol Exp Ther 283: 520–527
5. Jin F and Krzyzanski W (2004). Pharmacokinetic model of target-mediated disposition of thrombopoietin. AAPS PharmSci 6: 1–8